Unmet Needs in Current Treatment Approaches for Hypertrophic Cardiomyopathy (HCM)Premiere Date: Friday, July 16, 2021
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, July 16, 2022
Note: Credit Is No Longer Available
|Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
|Steve R. Ommen, MD, FACC, FAHA
Professor of Medicine, Mayo Clinic
Director, Mayo Hypertrophic Cardiomyopathy Clinic
Contemporary treatment strategies have transformed hypertrophic cardiomyopathy (HCM) from a common genetic heart disease with dire consequences to one that offers longevity and quality of life, however, it is imperative that clinicians stay up-to-date on the current guidelines for the management of HCM in order to optimize patient outcomes.
This CMEO Snack highlights the recommendations from the 2020 AHA/ACC Guidelines for the Diagnosis and Treatment of Patients with HCM, including the importance of multidisciplinary care and new agents that have the potential to improve care and outcomes of patients with HCM.
At the end of this CE activity, participants should be able to:
- Evaluate appropriate patients for HCM using evidence-based screening and diagnostic strategies.
Supported by an educational grant from Bristol Myers Squibb
Cardiologists, interventional cardiologists, electrophysiologists, internists, primary care clinicians, PAs, nurse practitioners, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
Note to PAs: PAs may claim a maximum of 0.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bhatt reports that he is a consultant for Abbott; Afimmune; AmarinCorporation; Amgen Inc.; Astra Zeneca; Bayer Corporation; Boehringer Ingelheim; Bristol Myers Squibb Company; Cardax, Inc.; Chiesi USA, Inc.; CSL Behring; Eisai Inc.; Ethicon USA, LLC; Ferring Pharmaceuticals: Forest Laboratories; Fractyl Laboratories, Inc.; HLS Therapeutics, Inc.; Idorsia Pharmaceuticals Ltd; Ironwood Pharmaceuticals, Inc.; Ischemix; Janssen Pharmaceuticals, Inc.; Lexicon Pharmaceuticals, Inc.; Lilly USA, LLC.; Medtronic; MyoKardia; Novo Nordisk; OWKIN, INC.; Pfizer Inc.; PhaseBio Pharmaceuticals, Inc.;PLx Pharma Inc.; Regeneron; Roche; Sanofi-Aventis U.S. LLC; Synaptic Pharmaceutical Corp.; and The Medicines Company.
Dr. Ommen has no disclosures to report.
Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).